Efgartigimod (FcRn) — Topline data
H2 2026
Thyroid eye disease (TED): Zai Lab partner argenx to provide topline results from two registrational UplighTED studies in the second half of 2026.Source filing
ZLAB biotech catalysts & pipeline
ZAI LAB LTD · Data as of 2026-09-08
Upcoming catalysts
ZL-1503 (IL-13/IL-31R) — Initial data
H2 2026
• Report initial first-in-human data from the SAD portion of the global Phase 1/1b study in healthy volunteers, including pharmacokinetics (PK), half-life, pharmacodynamic biomarkers (including pSTAT6), and safety, in the second half of 2026.Source filing
ZL-1311 — IND submission
Late 2026
• Submit an IND application in the U.S. by year-end 2026 and initiate a global Phase 1 study in the first half of 2027.Source filing
Povetacicept (APRIL/BAFF) — PDUFA
Nov 30
In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026.Source filing
Elegrobart — Topline data
2027
• Zai Lab to provide topline results from the China Phase 3 registrational study in 2027.Source filing
ZL-1222 (PD-1 / IL-12) — IND submission
2027
• Submit an IND application in the U.S. and initiate a global Phase 1 study in 2027.Source filing
ZL-1503 (IL-13/IL-31R) — Initial data
H1 2027
• Continue enrollment in the MAD portion of the Phase 1/1b study in patients with atopic dermatitis. Initial clinical data from the MAD portion expected in the first half of 2027.Source filing
ZL-6201 — Topline data
H1 2027
• Provide topline results from the dose escalation portion of the global Phase 1a/b study evaluating ZL-6201 in patients with sarcoma and selected tumors in the first half of 2027.Source filing
zocilurtatug pelitecan — Conference presentation
Oct 23–Oct 27
Global Phase 1 data for zocilurtatug pelitecan (zoci) in combination with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026; planned initiation of a registrational Phase 3 study later this yearSource filing